Table 2.

Outcomes overall and according to score on the ordinal scale

	Overall (n=43)	Initial 8-category ordinal scale (n=43)
		6	5	4
Clinical improvement*	3 (1–4), p<0.01†	3 (2–4)	2 (1–2)	2 (1–2)
Overall survival at the end of the study period	43 (100)	23 (53)	12 (28)	8 (19)
Time to recovery in days*	12 (9–25)	20 (14–31)	18 (13–34)	23 (15–29)
Bariciinib-related adverse events	0 (0)	0 (0)	0 (0)	0 (0)
8-category ordinal scale at day 14	3 (2–4)	23 (53)	12 (28)	8 (19)
1. Not hospitalised, no limitations of activities	6 (14)	3 (7)	1 (2)	2 (5)
2. Not hospitalised, limitation of activities, home oxygen requirement, or both	20 (47)	10 (23)	7 (16)	3 (7)
3. Hospitalised, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalisation was extended for infection control reasons)	3 (7)	1 (2)	0 (0)	2 (5)
4. Hospitalised, not requiring supplemental oxygen but requiring ongoing medical care (COVID-19-related or other medical conditions)	8 (19)	3 (7)	4 (9)	1 (2)
5. Hospitalised, requiring any supplemental oxygen	3 (7)	3 (7)	0 (0)	0 (0)
6. Hospitalised, requiring non-invasive ventilation or use of high-flow oxygen devices	3 (7)	3 (7)	0 (0)	0 (0)
7. Hospitalised, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation	0 (0)	0 (0)	0 (0)	0 (0)
8. Death	0 (0)	0 (0)	0 (0)	0 (0)
Days of treatment with baricitinib	6 (5–7)	6 (5.5–6)	6 (5–7)	5.5 (5–6.5)

Data are median (IQR) or n (%N).

*Clinical improvement was measured as the difference in the 8-category ordinal scale between day 14 and day 1 and time to recovery was defined as the day a patient reaches categories 1 or 2 on the 8-category ordinal scale since day 1.

†P values calculated with Wilcoxon rank-sum test.